\
&
Contact us
\
&
Contact us
This was 10 months ago
LocationOnline
ProgrammesThe European Partnership for Personalised Medicine has just launched a new opportunity for start-ups, researchers and early-stage teams working on cutting-edge solutions in personalised medicine.
Translating breakthrough innovations in personalised medicine (PM) into commercialised solutions that directly benefit patients remains a critical challenge in the healthcare industry. The absence of tailored business support often hinders the translation of scientific advancements & discoveries into market-ready solutions.
The EP PerMed Venture Creation Programme offers guidance from experienced mentors, ensuring that each project receives support throughout its journey. In this webinar, EP PerMed will provide an overview of the programme, including its requirements, the application process, and the support available, offering key insights for those interested in applying.
More information and registration here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
